?Megestrol Acetate | GMP-Certified Progestin API | USP/EP-Compliant Synthesis?
━━━━━━━━━━━━━━━━━━━━

?Product Overview?
Megestrol Acetate, a synthetic progestin derivative, is a critical intermediate in pharmaceutical manufacturing for hormone therapies and oncology treatments?13. It is widely used in hormone replacement regimens, appetite stimulation therapies, and as a key ingredient in oncology formulations targeting hormone-sensitive cancers?24. Compliant with USP/EP pharmacopeial standards, it ensures reliability in API production and clinical research applications?12.

?Key Advantages?
? ?≥98% HPLC-Verified Purity?: Meets USP/EP specifications for steroid APIs, validated through third-party testing?13.
? ?Stability-Tested?: 36-month shelf life under controlled storage (2-8°C, nitrogen-sealed packaging)?34.
? ?GMP-Certified Synthesis?: Full batch traceability with COA, including residual solvent (<20 ppm) and impurity profiling?24.

?Applications?
? ?Oncology Therapeutics?: Core component in breast and endometrial cancer treatment protocols?24.
? ?Hormone Replacement Therapy (HRT)?: Supports menopausal symptom management and metabolic disorder therapies?13.
? ?Appetite Stimulation?: FDA-approved for cachexia treatment in HIV/AIDS and cancer patients?34.

?Quality Certifications?
■ ?USP <467> Compliance?: Residual solvents (e.g., ethanol, acetone) below 30 ppm?12.
■ ?ISO 9001:2025?: Production processes with ≤0.5% inter-batch variability?34.

?Market Trends?
The global progestin API market is projected to grow at ?CAGR 6.8% through 2030?, driven by rising oncology R&D and aging population demands?13. Megestrol Acetate holds ?18% market share? in hormone therapy intermediates, with a 12% annual increase in biopharma procurement?24.